
|Videos|July 21, 2023
Key Retreatment Decisions in the Clinical Trials for Faricimab in nAMD
Author(s)Varun Chaudhary, MD, FRCS(C)
Dr Varun Chaudhary presents the retreatment decisions during the treat-and-extend phase of the TENAYA and LUCERNE clinical trials in neovascular AMD, focusing on the percentage of patients who maintained, extended, or reduced their treatment interval based on visual and anatomic criteria.
Advertisement
Episodes in this series
Newsletter
Keep your retina practice on the forefront—subscribe for expert analysis and emerging trends in retinal disease management.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Modern Retina
1
FLORetina 2025: Industry advances front and center at FLORetina Congress
2
Eichenbaum Acorns: Inside the mindset of an early adopter with Jordan M. Graff, MD, FACS
3
EyePoint receives second consecutive positive recommendation from DSMC
4
Q&A: Jay Chhablani discusses analysis of retinal vasculitis events with intravitreal agents
5

















































